News
RVMD
37.72
-1.90%
-0.73
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 22h ago
Erasca initiated with an Outperform at Raymond James
TipRanks · 23h ago
Weekly Report: what happened at RVMD last week (0317-0321)?
Weekly Report · 3d ago
Weekly Report: what happened at RVMD last week (0310-0314)?
Weekly Report · 03/17 09:15
Tracking Baker Brothers Portfolio - Q4 2024 Update
Seeking Alpha · 03/13 03:56
Weekly Report: what happened at RVMD last week (0303-0307)?
Weekly Report · 03/10 09:15
Analysts Expect 20% Gains Ahead For The Holdings of JHMM
NASDAQ · 03/04 12:05
Revolution Medicines Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/03 13:16
Revolution Medicines Price Target Raised to $73.00/Share From $72.00 by HC Wainwright & Co.
Dow Jones · 03/03 13:16
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $73
Benzinga · 03/03 13:06
Revolution Medicines price target raised to $73 from $72 at H.C. Wainwright
TipRanks · 03/03 11:20
REVOLUTION MEDICINES, INC. <RVMD.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $73 FROM $72
Reuters · 03/03 11:17
Weekly Report: what happened at RVMD last week (0224-0228)?
Weekly Report · 03/03 09:15
U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund
Reuters · 03/03 07:43
Analysts Are Bullish on Top Healthcare Stocks: uniQure (QURE), Revolution Medicines (RVMD)
TipRanks · 03/03 07:20
J.P. Morgan Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
TipRanks · 02/28 12:10
Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs
TipRanks · 02/28 01:52
Revolution Medicines Price Target Cut to $78.00/Share From $80.00 by Stifel
Dow Jones · 02/27 15:49
Revolution Medicines Is Maintained at Buy by Stifel
Dow Jones · 02/27 15:49
Stifel Maintains Buy on Revolution Medicines, Lowers Price Target to $78
Benzinga · 02/27 15:38
More
Webull provides a variety of real-time RVMD stock news. You can receive the latest news about Revolution Medicines, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.